<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2017</study_start_year><data_sharing_plan>IPD Sharing (as of April 2021): Undecided</data_sharing_plan><condition>Metastatic Colorectal Cancer</condition><condition>Colorectal Neoplasms</condition><disease>Metastatic Colorectal Cancer</disease><disease>Colorectal Neoplasms</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2242025</full_dataset_link><location>United States</location><study_start_month>4</study_start_month><keyword>Radiation Therapy</keyword><keyword>Tremelimumab</keyword><keyword>Durvalumab</keyword><keyword>17-139</keyword><keyword>Ablation</keyword><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer</name><description>The purpose of this study is to test the safety and effectiveness of two investigational drugs (drugs that are not currently approved by the FDA) given in combination with radiation therapy or ablation.</description><dates><creation>2017-04-15</creation></dates><accession>2242025</accession><cross_references><ClinicalTrials___gov>NCT03122509</ClinicalTrials___gov></cross_references></HashMap>